Health Economics›High-grade glioma pediatric›First-line therapy

First-line therapy

High-grade glioma pediatric · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Temozolomide and RT Variant #04	—	R 18 169	70d	~7.9 mo	~18.7 mo	~4	~R 72 677 PFS proxy · indirect	7
Vincristine and RT Variant #01	—	R 2 082	70d	—	—	—	—	—
VCP Variant #01 Partial	—	R 662	42d	—	—	—	—	—

3 of 3 regimens shown